Fig. 2.

CTLA-4 Ig (post) blocks costimulation through CD80/CD86/CD28 pathway. Tumor growth curves of C57BL/6J mice harboring B16F10 tumors initially treated with anti-CTLA-4 (clone 9H10). Once the initial treatments were completed, mice were further treated with CTLA-4 Ig (post) in combination with (A) anti-CD80 (post) and anti-CD86 (post) or (B) anti-CD28 (post). Dot-plot representation of frequency of CD45+ CD3− CD11c+ APCs that express (C) CD80+, (D) CD86+, (E) MHCI (H-2Db)+, (F) MHCII (I-A/I-E)+, and (G) PD-L1+ in tumor on day 24. (H) Representative FACS plots demonstrating percentages of CD45+ CD3− CD11c+ APCs that express CD80, CD86, MHCI (H-2Db), MHCII (I-A/I-E), and PD-L1. All experiments began with five mice per group. Representative experiment from duplicated experiments is shown.